Listed

ProtoKinetix, Inc.: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Oct 28, 2019 and accepted by EDGAR at Oct 25, 2019, 21:53 ET.

Share

Management's discussion and analysis

As filed, 13,442 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Unless the context requires otherwise, references in this document to “ProtoKinetix”, “we”, “our”, “us” or the “Company” are to ProtoKinetix, Incorporated.

The following discussion provides information regarding the results of operations for the nine month period ended September 30, 2019 and 2018, and our financial condition, liquidity and capital resources as of September 30, 2019, and December 31, 2018. The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this Quarterly Report on Form 10-Q include “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward looking statements as a result of certain factors, including, among others:

  • Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;
  • Our plans to develop and commercialize products from the AAGP® molecule;
  • Ongoing testing of the AAGP® molecule;
  • Our intellectual property position;
  • Our commercialization, marketing and manufacturing capabilities and strategy;
  • Our ability to retain key members of our senior management and key scientific consultants;
  • The effects of competition;
  • Our potential tax liabilities resulting from conducting business in the United States and Canada;
  • The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and
  • Our common stock’s limited trading history.

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in our filings with the SEC under the Exchange Act and the Securities Act, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph and elsewhere in this Quarterly Report. Other than as required under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Business Overview

ProtoKinetix, Incorporated is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGP®. The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGP® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP® to market.

Results of Operations

The following table shows selected financial data and operating results for the periods noted. Following the table, please see management’s discussion of significant changes.

For the Nine Months Ended September 30, 2019 2018
Revenues $— $—
Cost of Sales — —
Gross (Loss) Profit — —
Operating Expenses
Amortization $2,250 $2,250
General and Administrative 202,238 56,757
Professional Fees 92,315 98,274
Research and Development 279,089 247,896
Share-Based Compensation 1,167,629 614,427
Total Operating Expenses 1,167,629 1,019,604
Loss from Operations (1,743,521) (1,019,604)
Other Income
Foreign Exchange Loss (106) (3,073)
Total Other Loss (106) (3,073)
Net Loss $(1,743,627) (1,022,677)

Revenues

We had no revenues for the nine month periods ended September 30, 2019 and 2018.

Gross Profit and Expenses

The Company’s net loss was $1,743,627 for the nine month period ended September 30, 2019 compared to $1,022,677 for the nine month period ended September 30, 2018. These expenses were primarily incurred for professional fees, consulting services related to the operations of the Company’s business, research and development and other general and administrative expenses. Significant changes from the prior nine month period ended September 30, 2018 include:

General and Administrative fees increased by $145,481 from $56,757 to $202,238 primarily as a result of an increase in spending on advertising and investor relations, and the upgrade of company website.

Research and development increased slightly year over year with a change of $31,193 from $247,896 to $279,089 with the primary spending being testing of effects of glycopeptides on retinal cell transplants, stem cell engraftment and antibody production with the University of British Columbia (UBC). Added expenses from new research being done at the University of Dalhousie, and the order placement for additional production of our AAGP molecule to be delivered by year end.

Share-based compensation increased significantly by $553,202 from $614,427 to $1,167,629 primarily as a result of an increase in the value of management stock options for the current year, and the addition of stock option compensation to investor relations consultants.

Liquidity and Capital Resources

The following summarizes our statements of cash flows at September 30, 2019 and December 31, 2018:

September 30, 2019 December 31, 2018
Cash $289,859 $136,029
Working Capital $295,029 $58,194

24

At September 30, 2019, we had $289,859 in cash and $300,449 in total current assets. As of September 30, 2019, we had a positive working capital equity position of $295,029. Based upon our working capital equity as of September 30, 2019, we will require additional equity and/or debt financing in order to meet cash flow projections and carry forward our business objectives.

There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our new business. The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.

Sources and Uses of Cash

Net Cash Used in Operating Activities

Net cash used in operating activities increased by $280,215 from $376,537 to $656,752 for the nine months ended September 30, 2018 and 2019, respectively. This increase was predominantly due to an increase in research spending.

Net Cash Used in Investing Activities

Net cash used in investing activities was $6,418 for the nine month period ended September 30, 2019 while the Company had net cash used in investing activities of $27,946 for the comparative period. The difference is attributable to a decrease in the purchase of intangible assets.

Net Cash Provided by Financing Activities

Net cash provided by financing activities increased by $604,962 from $212,038 to $817,000 for the nine months ended September 30, 2018 and 2019, respectively due to an increase of funding from private placements.

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which contemplate continuation of the Company as a going concern. The history of losses and the inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock. However, the price and volume of the Company’s common stock is volatile.

Off-Balance Sheet Arrangements

None.

Contractual Obligations

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements.

Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-Q.

While all of the significant accounting policies are important to the Company’s financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

Share-Based Compensation

On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the “Plan”). The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services outside of the Plan, and beginning July 1, 2015 and ending December 31, 2016 pursuant to the Plan. On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”).

On November 9, 2018, the Board amended the 2017 Plan to increase the aggregate number of shares that may be issued under the 2017 Plan from 30,000,000 to 50,000,000 shares subject to adjustment as provided therein to continue to incentivize contractors and future employees (if any) of the Company.

On July 15, 2019 , the Board amended the 2017 Plan to increase the aggregate number of shares that may be issued under the 2017 Plan from 50,000,000 to 89,700,000 shares subject to adjustment as provided therein to continue to incentivize contractors and future employees (if any) of the Company

During the nine month period ended September 30, 2019, the Company granted 32,500,000 additional options pursuant to the 2017 Plan. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.

The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Sales and Marketing

The Company is currently not selling or marketing any products.

Inflation

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine months ended September 30, 2019.

Market risk

As filed, 139 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

Controls and procedures

As filed, 2,568 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (the “1934 Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the 1934 Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, under the direction of our Chief Executive Officer (who is our principal executive officer), and Chief Financial Officer (who is our principal accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as required by 1934 Act Rule 13a-15(b) as of September 30, 2019 (the end of the period covered by this report). Based on that evaluation, our principal executive officer and our principal accounting officer concluded that these disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

The Company, including its Chief Executive Officer and Chief Financial Officer, does not expect that its internal controls and procedures will prevent or detect all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated by the SEC under the 1934 Act) during the nine months ended September 30, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 364 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. However, our current risk factors are set forth in our Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on March 12, 2019, and such risk factors are incorporated herein by this reference.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2019-07-01 to 2019-09-30$140.9kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$279.1kus-gaap:ResearchAndDevelopmentExpense
Net income3 months2019-07-01 to 2019-09-30−$591.9kus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30−$1.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2019-07-01 to 2019-09-30272,816,256 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2019-01-01 to 2019-09-30267,232,714 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2019-01-01 to 2019-09-30−$656.8kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-09-30$289.9kus-gaap:Cash
Current assetsAt period end2019-09-30$300.4kus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$492.4kus-gaap:Assets
Current liabilitiesAt period end2019-09-30$5.4kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2019-09-30$487.0kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001079973-19-000540. Last ingested by Listed: Nov 4, 2026, 19:28 ET. Listed shows no prices and gives no investment advice.